<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17701" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Antinuclear Antibodies (ANA)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nosal</surname>
            <given-names>Rebecca S.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Superville</surname>
            <given-names>Shervonne S.</given-names>
          </name>
          <aff>Port Of Spain General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amraei</surname>
            <given-names>Razie</given-names>
          </name>
          <aff>Boston University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Varacallo</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Penn Highlands Healthcare System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Nosal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shervonne Superville declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Razie Amraei declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Varacallo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17701.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The antinuclear antibody&#x000a0;(ANA) is a defining feature of autoimmune connective tissue disease. ANAs are a class of antibodies that bind to cellular components in the nucleus, including proteins, DNA, RNA, and nucleic acid-protein complexes.<xref ref-type="bibr" rid="article-17701.r1">[1]</xref> First described in 1948,&#x000a0;ANA identification has been the foundation of diagnosis for autoimmune connective tissue disease, including systemic lupus erythematosus (SLE), Sjogren's syndrome, and polymyositis/dermatomyositis.<xref ref-type="bibr" rid="article-17701.r2">[2]</xref> Although&#x000a0;20&#x000a0;to 30%&#x000a0;of the average population has detectable levels of ANAs, increased titers are characteristic of individuals with connective tissue disorders.<xref ref-type="bibr" rid="article-17701.r3">[3]</xref> Thus, the sensitivity and specificity of the methods used to detect ANAs are crucial to diagnosis.</p>
      </sec>
      <sec id="article-17701.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>Antinuclear antibodies (ANA) refer to an autoantibody directed at material within the nucleus of a cell. ANAs are typically classified into two groups, antibodies to DNA and histones and antibodies to nuclear material. Antibodies to DNA and histones include anti-dsDNA antibodies and anti-histone antibodies. The remaining category includes an additional targeted nuclear antigen. The first&#x000a0;to be identified&#x000a0;in this category was the anti-Smith antibody.<xref ref-type="bibr" rid="article-17701.r3">[3]</xref> Others include anti-SSA/Ro, anti-SSB/La, anti-U3-RNP, anticentromere, Scl-70, and Jo-1.<xref ref-type="bibr" rid="article-17701.r4">[4]</xref><xref ref-type="bibr" rid="article-17701.r5">[5]</xref></p>
      </sec>
      <sec id="article-17701.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Given that ANAs are present in up to 30% of the average healthy population, there are inherent challenges against using them to diagnose autoimmune connective tissue disorders. Positive results must be interpreted with the existing clinical manifestations to establish a diagnosis. Furthermore, initial immunofluorescence testing on HEp-2 (human epithelial laryngeal carcinoma type 2) cells subjectively depends on multiple factors, including the laboratory manufacturing the substrate cells, the skill of the&#x000a0;individual&#x000a0;reading the result, and the definition of a positive result in each laboratory.<xref ref-type="bibr" rid="article-17701.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17701.s4" sec-type="Molecular Level&#x0000d;&#x0000a;">
        <title>Molecular Level
</title>
        <p>ANAs bind to various molecular compounds with the cell's nucleus, including nucleic material and proteins. Antibodies may bind to double-stranded DNA (anti-dsDNA), and studies suggest that&#x000a0;antibodies are formed during the incomplete removal of cellular material during apoptosis.<xref ref-type="bibr" rid="article-17701.r7">[7]</xref><xref ref-type="bibr" rid="article-17701.r8">[8]</xref> Additionally, anti-Sm antibodies bind to the Smith protein, a&#x000a0;protein contained within small nuclear ribonucleoprotein (snRNP) particles.&#x000a0;Scl-70 antibodies interfere with DNA replication by binding to Topoisomerase I, and anti-centromere antibodies affect cell division by binding to centromeres during interphase.<xref ref-type="bibr" rid="article-17701.r9">[9]</xref><xref ref-type="bibr" rid="article-17701.r10">[10]</xref><xref ref-type="bibr" rid="article-17701.r9">[9]</xref><xref ref-type="bibr" rid="article-17701.r11">[11]</xref>&#x000a0;</p>
        <p>Antibodies to Jo-1 prevent histidine binding to tRNA during protein synthesis by targeting histidyl-tRNA synthetase.<xref ref-type="bibr" rid="article-17701.r12">[12]</xref> Additionally,&#x000a0;antibodies may target the Ro/SSA antigen, an amino acid sequence that binds to double-stranded and single-stranded DNA. The suspected mechanism is that they may bind to viral DNA of&#x000a0;the Epstein Barr virus (EBV) with molecular mimicry, later&#x000a0;causing autoimmune disease. Unlike Ro, La/SSB is a protein found primarily in the nucleus. But similar to Ro, La is also known to bind to nuclear material from EBV.<xref ref-type="bibr" rid="article-17701.r13">[13]</xref></p>
      </sec>
      <sec id="article-17701.s5" sec-type="Testing">
        <title>Testing</title>
        <p>The origins of&#x000a0;ANA testing were first described in 1948 when Hargraves and colleagues observed a specific cell from a patient with systemic lupus erythematosus (SLE) and termed it the "L.E. cell."<xref ref-type="bibr" rid="article-17701.r14">[14]</xref>. The following experiments used cells from mice and rat kidneys as the substrate&#x000a0;for indirect immunofluorescence (IIF) staining and established the foundations of IIF testing for detecting ANA.<xref ref-type="bibr" rid="article-17701.r1">[1]</xref>&#x000a0;In the most commonly used method for ANA detection, the patient's serum antibodies interact with fixed HEp-2 cells and form distinct fluorescent patterns (see <bold>Image.</bold> Antinuclear&#x000a0;Antibody&#x000a0;Fluorescence&#x000a0;Patterns Diagram).<xref ref-type="bibr" rid="article-17701.r15">[15]</xref></p>
        <p>In 1975, HEp-2 cells became the standard cell substrate due to their increased sensitivity. And in 2010, the American College of Rheumatology published a study affirming that indirect immunofluorescence (IIF) staining with HEp-2 cells should be considered the gold standard for detecting ANAs. However, due to variability in technique, HEp-2 preparation, and antibody expression, HEp-2 IIF results may be difficult to standardize.<xref ref-type="bibr" rid="article-17701.r16">[16]</xref></p>
        <p>IIF patterns correlate to specific ANA subtypes, and pattern recognition is a valuable tool in ANA testing. Homogenous fluorescence pattern typically suggests antibodies directed at dsDNA, histones, or nucleosomes.<xref ref-type="bibr" rid="article-17701.r1">[1]</xref> A membranous pattern may&#x000a0;show antibodies to membrane proteins. Antibodies directed to other nuclear antigens correlate with speckled fluorescent patterns. Anti-Smith antibodies fluoresce in a course-speckled pattern. Anti-SSA/Ro and anti-SSB/La form a fine-speckled pattern. Discrete speckles represent antibodies targeted to the centromeres in cells undergoing interphase. Nucleolar speckles are associated with antibodies directed at DNA topoisomerase (Scl-70). The speckled cytoplasmic pattern suggests antibodies to aminoacyl-tRNA synthetase (Jo-1).<xref ref-type="bibr" rid="article-17701.r1">[1]</xref></p>
        <p>While IIF-ANA remains the primary initial testing method, other methods, including&#x000a0;enzyme-linked&#x000a0;immunosorbent assays (ELISA) and immunoassays, offer confirmatory testing for specific ANAs. ELISA offers quantitative screening for specific ANAs and has proven to perform&#x000a0;comparably to IIF, and commercial panels for antibodies to SSA/Ro, SSB/La, Sm, Scl-70, Jo-1, and centromeres are available.<xref ref-type="bibr" rid="article-17701.r17">[17]</xref>&#x000a0;In addition, multiplex&#x000a0;immunoassays offer similar benefits and use a series of known antigen-coated beads, and when combined with patient serum, indicate&#x000a0;their specific antibody targets.<xref ref-type="bibr" rid="article-17701.r18">[18]</xref></p>
      </sec>
      <sec id="article-17701.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Systemic autoimmune disorders affect 3-5% of the general population, and ANAs are&#x000a0;one of the few specific disease markers in their diagnosis.<xref ref-type="bibr" rid="article-17701.r16">[16]</xref> Therefore, ANA testing is often the first step in diagnosing systemic autoimmune connective tissue disorders. Laboratories report the staining pattern and the titer of ANA as an indication for further testing. The presence of&#x000a0;ANAs and their subtypes increase the likelihood of a systemic autoimmune disorder, and there are notable clinical correlations between the ANA subtypes and autoimmune connective tissue disorders. However,&#x000a0;they do not&#x000a0;necessarily&#x000a0;confirm that an individual has or will develop an autoimmune disease. Although positive ANA results help diagnose several autoimmune disorders, the negative ANA titer is also expected in some specific inflammatory conditions, for instance, ankylosing spondylitis.<xref ref-type="bibr" rid="article-17701.r19">[19]</xref></p>
        <p>
<bold>Systemic Lupus Erythematosus&#x000a0;(SLE)</bold>
</p>
        <p>Systemic Lupus Erythematosus (SLE)&#x000a0;is a chronic autoimmune disorder that affects nearly every system in the body. Individuals have variations in disease presentation, where one system often deteriorates significantly more than the others. Clinical manifestations may include fatigue, arthritis, vasculitis, nephritis, pleuritis, and&#x000a0;myocarditis. Clinical manifestations and&#x000a0;immunologic criteria&#x000a0;are required&#x000a0;to establish a definitive diagnosis of SLE. Immunologic criteria include&#x000a0;abnormal ANA titers&#x000a0;in the absence of&#x000a0;drugs and the presence of&#x000a0;anti-dsDNA or anti-Sm antibodies.<xref ref-type="bibr" rid="article-17701.r20">[20]</xref></p>
        <p>
<bold>Scleroderma</bold>
</p>
        <p>Scleroderma, or systemic sclerosis, involves progressive fibrosis of the skin and organs. Scleroderma presents either as a limited form or a diffuse cutaneous form. The diagnostic basis is a combination of clinical symptoms and increased ANA titers. Scl-70 is highly correlated&#x000a0;with scleroderma,&#x000a0;while&#x000a0;anti-centromere antibodies are moderately correlated.<xref ref-type="bibr" rid="article-17701.r21">[21]</xref></p>
        <p>
<bold>Myositis</bold>
</p>
        <p>Polymyositis (PM)&#x000a0;and&#x000a0;dermatomyositis&#x000a0;(DM) are a group of inflammatory disorders that primarily affect the proximal muscles and cause inflammation. The primary clinical manifestation of PM&#x000a0;is the gradual weakening of the proximal muscles. Likewise, DM presents with gradually increasing proximal weakness. Still, cutaneous symptoms such as facial erythema, poikiloderma in sun-exposed areas, and Gottron's papules on the extensor surfaces of the hands are also present. General ANA testing is used to diagnose PM and DM, while&#x000a0;anti-Jo1 antibodies are associated&#x000a0;with 30% of patients with PM/DM.<xref ref-type="bibr" rid="article-17701.r3">[3]</xref></p>
        <p>
<bold>Sjogren's</bold>
</p>
        <p>Sjogren's syndrome is a chronic autoimmune pathology that destroys the exocrine glands, including the lacrimal and salivary glands. Diagnosis centers on clinical manifestations and serologic testing. Clinical manifestations of Sjogren's syndrome include chronic dry eye, dry mouth, Raynaud's phenomenon, arthritis, and bronchitis. When there is a suspicion of Sjogren's syndrome, testing for anti-Ro/SSA and anti-La/SSB titers is the protocol.<xref ref-type="bibr" rid="article-17701.r13">[13]</xref></p>
        <p>
<bold>Psoriatic Arthritis</bold>
</p>
        <p>Psoriatic arthritis is a subtype of inflammatory arthritis seen in association with associated with psoriasis (a member of the spondyloarthritis family). This condition can present a diagnostic challenge for clinicians as the clinical presentation can be relatively subtle. There are several case reports regarding the potential long-term consequences and conditions associated with psoriatic arthritis, and these associations can ultimately compromise the patient's outcome.<xref ref-type="bibr" rid="article-17701.r22">[22]</xref>&#x000a0;ANA testing has long been thought to be a diagnostic tool and potentially detectable serum marker to enhance clinical recognition of the condition. A study in 2015 found an increase in the serum levels of ANA antibodies in patients with psoriatic arthritis compared to healthy controls.<xref ref-type="bibr" rid="article-17701.r23">[23]</xref>&#x000a0;Of note, the cohort under investigation excluded other confounding conditions (e.g., rheumatoid arthritis, etc.) known to result in an elevated serum ANA level.</p>
      </sec>
      <sec id="article-17701.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17701&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17701">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17701/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17701">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17701.s8">
        <fig id="article-17701.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Antinuclear Antibody Fluorescence Patterns Diagram Created and contributed by R Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_ANA__Patterns" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17701.s9">
        <title>References</title>
        <ref id="article-17701.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muro</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Antinuclear antibodies.</article-title>
            <source>Autoimmunity</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">15804699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Del Mercado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.</article-title>
            <source>Mod Rheumatol</source>
            <year>2009</year>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-28</page-range>
            <pub-id pub-id-type="pmid">19277826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minz</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited.</article-title>
            <source>Diagn Pathol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>02</day>
            <volume>4</volume>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">19121207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishigatsubo</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological roles of Ro/SSA autoantibody system.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>606195</fpage>
            <pub-id pub-id-type="pmid">23304190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prince</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hogrefe</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a line immunoblot assay for detection of antibodies recognizing extractable nuclear antigens.</article-title>
            <source>J Clin Lab Anal</source>
            <year>1998</year>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>320</fpage>
            <page-range>320-4</page-range>
            <pub-id pub-id-type="pmid">9773966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tebo</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies.</article-title>
            <source>Clin Vaccine Immunol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29021301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisetsky</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>New insights into the role of antinuclear antibodies in systemic lupus erythematosus.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>565</fpage>
            <page-range>565-579</page-range>
            <pub-id pub-id-type="pmid">32884126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dieker</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van der Vlag</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berden</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Deranged removal of apoptotic cells: its role in the genesis of lupus.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <page-range>282-5</page-range>
            <pub-id pub-id-type="pmid">14736945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Migliorini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anti-Sm and anti-RNP antibodies.</article-title>
            <source>Autoimmunity</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-54</page-range>
            <pub-id pub-id-type="pmid">15804705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gussin</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Ignat</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teodorescu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus.</article-title>
            <source>Arthritis Rheum</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-83</page-range>
            <pub-id pub-id-type="pmid">11229469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Venencie-Lemarchand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spurbeck</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schroeter</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>The anticentromere antibody: disease specificity and clinical significance.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>700</fpage>
            <page-range>700-6</page-range>
            <pub-id pub-id-type="pmid">6384675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zampieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghirardello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iaccarino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tarricone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gambari</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anti-Jo-1 antibodies.</article-title>
            <source>Autoimmunity</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-8</page-range>
            <pub-id pub-id-type="pmid">15804708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reinisch</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Structural and biochemical basis for misfolded RNA recognition by the Ro autoantigen.</article-title>
            <source>Nat Struct Mol Biol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1002</fpage>
            <page-range>1002-9</page-range>
            <pub-id pub-id-type="pmid">17041599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HARGRAVES</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>RICHMOND</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>MORTON</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Presentation of two bone marrow elements; the tart cell and the L.E. cell.</article-title>
            <source>Proc Staff Meet Mayo Clin</source>
            <year>1948</year>
            <month>Jan</month>
            <day>21</day>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>25</fpage>
            <page-range>25-8</page-range>
            <pub-id pub-id-type="pmid">18921142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peene</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Meheus</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>De Keyser</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>1131</fpage>
            <page-range>1131-6</page-range>
            <pub-id pub-id-type="pmid">11709455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisetsky</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Antinuclear antibody testing - misunderstood or misbegotten?</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>495</fpage>
            <page-range>495-502</page-range>
            <pub-id pub-id-type="pmid">28541299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Fritzler</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Emerging technologies in autoantibody testing for rheumatic diseases.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2017</year>
            <month>Jul</month>
            <day>24</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <pub-id pub-id-type="pmid">28738887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases.</article-title>
            <source>Front Immunol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>181</fpage>
            <pub-id pub-id-type="pmid">25954274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Buchanan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Sacroiliitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28846269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orbai</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alarc&#x000f3;n</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Fortin</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Isenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nived</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sturfelt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ramsey-Goldman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hanly</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Guerrero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aranow</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Urowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kalunian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Costner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Zoma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernatsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruiz-Irastorza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buyon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Maddison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dooley</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Ginzler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stoll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peschken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jorizzo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Callen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Fessler</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Inanc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steinsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Sigler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McGwin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Magder</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>2677</fpage>
            <page-range>2677-86</page-range>
            <pub-id pub-id-type="pmid">22553077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobolewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ma&#x0015b;li&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wieczorek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00141;agun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Malewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roszkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nitskovich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Szyma&#x00144;ska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walecka</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Systemic sclerosis - multidisciplinary disease: clinical features and treatment.</article-title>
            <source>Reumatologia</source>
            <year>2019</year>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-233</page-range>
            <pub-id pub-id-type="pmid">31548749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bent</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frauenhoffer</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Lipoma Arborescens and Coexisting Psoriatic Arthritis: A Case Report and Review of the Literature.</article-title>
            <source>JBJS Case Connect</source>
            <year>2013</year>
            <season>Oct-Dec</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>e121</fpage>
            <pub-id pub-id-type="pmid">29252521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17701.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silvy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Auger</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Guzian</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mattei</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Guis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roudier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balandraud</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>e0134218</fpage>
            <pub-id pub-id-type="pmid">26230924</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
